VIVUS Sees Unusually High Options Volume (VVUS)
VIVUS (NASDAQ:VVUS) saw unusually large options trading activity on Monday. Traders bought 8,245 put options on the company, ARN reports. This represents an increase of 203% compared to the typical volume of 2,724 put options.
In other VIVUS news, CFO Timothy E. Morris sold 10,654 shares of the company’s stock on the open market in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $11.95, for a total value of $127,315.30. The transaction was disclosed in a filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on VVUS shares. Analysts at Lazard Capital Markets downgraded shares of VIVUS (NASDAQ:VVUS) from a “neutral” rating to a “sell” rating in a research note to investors on Wednesday, September 4th. They now have a $8.00 price target on the stock. Separately, analysts at JMP Securities downgraded shares of VIVUS (NASDAQ:VVUS) from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, September 3rd. Finally, analysts at Credit Suisse cut their price target on shares of VIVUS (NASDAQ:VVUS) from $15.00 to $14.00 in a research note to investors on Wednesday, August 7th. They now have a “neutral” rating on the stock.
Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. VIVUS currently has a consensus rating of “Hold” and a consensus target price of $16.00.
Shares of VIVUS (NASDAQ:VVUS) traded down 1.47% on Tuesday, hitting $10.76. The stock had a trading volume of 297,003 shares. VIVUS has a 1-year low of $9.86 and a 1-year high of $24.86. The stock’s 50-day moving average is $13.12 and its 200-day moving average is $12.70. The company’s market cap is $1.085 billion.
VIVUS (NASDAQ:VVUS) last announced its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.11. The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $12.76 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. Analysts expect that VIVUS will post $-1.97 EPS for the current fiscal year.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.